-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Neurocrine Biosciences, Raises Price Target to $198

Benzinga·07/31/2026 19:23:35
语音播报
RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target from $195 to $198.